Choosing a citicoline supplement is mostly a label-reading job. Citicoline (CDP-choline) is sold in the United States as a dietary supplement, not an FDA-approved drug, and CDP-choline and citicoline are two names for the same compound. Cognizin is a brand of it. Once you know that, the real work is checking the dose, the form, the quality signals on the label, and whether the claims on the bottle match what studies have actually shown.
It helps to be honest about what the evidence says before you shop. In acute stroke, the large ICTUS trial (Dávalos, Lancet 2012, about 2,300 people) found no improvement in 90-day recovery versus placebo. In traumatic brain injury, the COBRIT trial (Zafonte, JAMA 2012) found no improvement in functional or cognitive outcomes versus placebo. Smaller trials in healthy adults and adolescents suggest possible attention benefits, but they are small and industry funded. So a good product is one that makes modest claims, states its dose clearly, and does not promise to treat disease.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Evidence at a glance
| Question | Best evidence | Tier | Bottom line |
|---|---|---|---|
| What is citicoline, and is it the same as CDP-choline? | Naming and chemistry references | T3b/T4 | They are the same compound; Cognizin is a brand of it. |
| Does the label tell me the real dose? | Label-reading guidance (no disease trial applies) | , | Doses in trials ranged from 250 to 2,000 mg/day; the label should state milligrams per capsule clearly. |
| Is citicoline an approved drug in the US? | Regulatory status | , | No. It is a dietary supplement and is not FDA-approved to treat any condition. |
| Is there good evidence for attention in healthy people? | McGlade 2012 (women, 250/500 mg, Cognizin-funded); McGlade (adolescent males, Cognizin-funded) | T1 small | Better attention-test scores, but trials were small and industry funded. |
| Is it safe? | Trial safety data | T1/T2 | Generally well tolerated at 250, 2,000 mg/day; mild GI upset, headache, insomnia. Pregnancy and breastfeeding data are lacking. |
Start with the name on the label
The single most confusing part of shopping is the naming. A bottle may say "citicoline," "CDP-choline," or "citicoline (as Cognizin)." All of these refer to the same molecule. "Cognizin" is simply a branded form made to a defined specification, and several of the published attention studies used it. A product listing "citicoline (as Cognizin)" is not a different or stronger compound; it is the same compound from a named supplier. Our overview of what citicoline is and how it works goes deeper on the chemistry, and the page on Cognizin as a branded form of citicoline explains the trademark in detail.
Read the dose, not the marketing
Clinical trials have generally used between 250 and 2,000 mg per day. A trustworthy label tells you exactly how many milligrams of citicoline are in each capsule and how many capsules make a serving. Be cautious with "proprietary blends" that hide the citicoline amount inside a mixture of other ingredients, because you cannot compare that product to the doses used in studies. For a fuller discussion of studied amounts, see our page on citicoline dosage and safety. We do not give personal dosing advice; the right amount for you is a conversation with your clinician, especially if you take other medicines.
Match the claims to the evidence
A red flag is any label or advertisement implying citicoline treats stroke, traumatic brain injury, or ADHD. The two largest modern trials, ICTUS in stroke and COBRIT in brain injury, found no benefit versus placebo. Earlier stroke meta-analyses had suggested benefit, but that was not confirmed by ICTUS. There are also no adequate trials in ADHD, so there is no good evidence citicoline treats it. What small evidence exists for healthy people is narrower: better scores on attention tests in women at 250 or 500 mg (McGlade 2012) and attention and psychomotor speed gains in adolescent males, both small and funded by the maker of Cognizin. A responsible product stays within that modest territory. Our citicoline supplements overview covers how these products are positioned in the market.
Quality signals worth checking
Because supplements are not pre-approved like drugs, quality depends on the manufacturer. Practical signals include a stated amount of citicoline per capsule, a named ingredient form (such as Cognizin, where used), batch or lot numbers, an expiration date, and third-party testing or a certificate of analysis. Avoid products that bundle citicoline with long lists of stimulants or make disease-treatment claims, since those claims are both unsupported and a sign of loose regulatory discipline.
Safety and interactions to keep in mind
Citicoline is generally well tolerated at 250, 2,000 mg/day in trials, with mild side effects such as stomach upset, headache, and insomnia. Data in pregnancy and breastfeeding are lacking, so use in those situations is not supported by evidence. One specific interaction matters: citicoline may enhance the effects of levodopa, so people with Parkinson's disease should involve their neurologist before taking it. Anyone on regular medication should do the same with their own clinician.
Expert insight
I want readers to hear this clearly from me: citicoline and CDP-choline are the same compound, and in the United States it is a dietary supplement, not an FDA-approved drug. The strongest modern trial evidence we have is actually negative, the ICTUS trial in acute stroke and the COBRIT trial in traumatic brain injury both showed no benefit over placebo. The positive findings in healthy adults and adolescents come from small, industry-funded studies of attention, which I treat as preliminary. When patients ask me how to choose a product, I tell them the decision is about label transparency and honest claims, not about finding a magic brand. Citicoline may support membrane phospholipid synthesis, but the neuroprotection story is preclinical, and I would not promise more than the data allow. If you take levodopa or any regular medication, please involve your physician before starting it.
Questions readers ask
Are citicoline and CDP-choline different products?
No. They are two names for the same compound. A label may use either name, and the ingredient is identical.
Is Cognizin better than generic citicoline?
Cognizin is a branded form of citicoline with a defined manufacturing specification, and it was used in the McGlade attention studies. It is not a different compound. Whether a given generic matches its quality depends on the manufacturer, which is why third-party testing matters.
What dose should a label show?
Trials have used 250 to 2,000 mg per day. A good label states the milligrams of citicoline per capsule clearly. Avoid products that hide the amount inside a proprietary blend.
Can citicoline help after a stroke or brain injury?
The best modern evidence says no. ICTUS (Lancet 2012, about 2,300 people) found no improvement in 90-day stroke recovery versus placebo, and COBRIT (JAMA 2012) found no benefit in traumatic brain injury. Earlier meta-analyses suggested benefit but were not confirmed by ICTUS.
Does citicoline treat ADHD?
There are no adequate trials in ADHD. There is no good evidence citicoline treats ADHD, and any product implying otherwise is overstepping the science.
What side effects should I know about?
In trials, citicoline was generally well tolerated. The most common complaints were mild stomach upset, headache, and insomnia. Safety data in pregnancy and breastfeeding are lacking.
Does citicoline interact with any medicines?
It may enhance the effects of levodopa. People with Parkinson's disease should involve their neurologist before using it, and anyone on regular medication should check with their clinician.
Sources
The studies behind this article include: Dávalos et al., the ICTUS trial in acute stroke (Lancet, 2012); Zafonte et al., the COBRIT trial in traumatic brain injury (JAMA, 2012); Fioravanti and Yanagi, the Cochrane review on chronic cerebrovascular cognitive decline; Cotroneo et al., the IDEALE observational study in mild vascular cognitive impairment; McGlade et al. (2012) on attention in adult women; and McGlade et al. on attention in adolescent males. PMIDs are not listed until each one is confirmed on PubMed.
